Study: A 52-week, randomised, double-blind, double-dummy, parallel group,
multi-centre, non-inferiority study assessing exacerbation rate, additional measures of
asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 compared with mepolizumab or benralizumab
Please Select Your Affiliation with CU Anschutz
Thank you for expressing your interest in a research study and for taking the time to provide your information.
By clicking 'Submit', your information will be shared with the research team. Typically a member of the research team will contact you within 1 to 2 business days.
Please understand that:
- The research team will need to determine whether you are eligible for the study. Clicking 'Submit' does not enroll you into the study, or guarantee that you qualify for the study.
- It is always your choice to participate.
Thanks again. Volunteers such as yourself are at the core of our work.